{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T21:56:44Z","timestamp":1794779804887,"version":"4.9.1"},"reference-count":35,"publisher":"Bentham Science Publishers Ltd.","issue":"17","funder":[{"name":"Wuhan Medical Research Project","award":["WZ19Q02"],"award-info":[{"award-number":["WZ19Q02"]}]},{"DOI":"10.13039\/501100007046","name":"Innovative Seed Funds of the Medical College of Wuhan University","doi-asserted-by":"publisher","award":["TFZZ2018027"],"award-info":[{"award-number":["TFZZ2018027"]}],"id":[{"id":"10.13039\/501100007046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>miR-122 is upregulated in non-alcoholic fatty liver disease (NAFLD) liver\ntissue, and knockdown of miR-122 protects hepatocytes from lipid metabolism disorders. This\nstudy aimed to investigate whether Huazhi Rougan Granule (HRG) alleviates NAFLD liver and\nintestinal injury by regulating the miR-122-mediated TLR4\/MyD88\/NF-\u03baB pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Rats with NAFLD were constructed by high-fat feeding. Serum levels of total cholesterol\n(TC), triglycerides (TG), aspartate aminotransferase (AST), and alanine aminotransferase\n(ALT) were measured using a fully automated biochemical instrument. Histopathological\nchanges in the liver and small intestine were observed by HE staining. QRT-PCR detected the\nexpression level of miR-122 in the liver tissues. The protein expression of TLR4, MyD88, NF-\n\u03baB p65, and p-p65 in liver tissues was detected by western blotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>HRG slowed down the weight gain of NAFLD rats, decreased (P&lt;0.05) the levels of\nTC, TG, ALT, AST, TNF-\u03b1, IL-1\u03b2, IL-6, LPS, and Hpt, improved the pathological status of liver\nand small intestine tissues, upregulated (P&lt;0.05) the expression of ZO-1 and Occludin, downregulated\n(P&lt;0.05) the protein expression of TLR4, MyD88, and p-p65, and inhibited (P&lt;0.05)\nthe expression of miR-122.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HRG may alleviate hepatic and intestinal injuries in rats with NAFLD by regulating\nthe miR-122-mediated TLR4\/MyD88\/NF-\u03baB pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113862073290372240603090844","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:51:31Z","timestamp":1732071091000},"page":"3002-3009","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Huazhi Rougan Granule Alleviates Liver and Intestinal Damage in Non-Alcoholic Fatty Liver Disease by Regulating miR-122 Expression and TLR4\/MyD88\/NF-\u03baB Pathway Activation"],"prefix":"10.2174","volume":"28","author":[{"given":"Ping","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, P. R, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming 650019, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, P. R, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, P. R, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41575-020-00406-0","volume":"18","author":"Abdelmalek M.F.","year":"2021","unstructured":"Abdelmalek M.F.; Nonalcoholic fatty liver disease: Another leap forward. Nat Rev Gastroenterol Hepatol  2021,18(2),85-86","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","volume":"18","author":"Maurice J.","year":"2018","unstructured":"Maurice J.; Manousou P.; Non-alcoholic fatty liver disease. Clin Med (Lond)  2018,18(3),245-250","journal-title":"Clin Med (Lond)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"dmm039206","DOI":"10.1242\/dmm.039206","volume":"12","author":"Carbajo-Pescador S.","year":"2019","unstructured":"Carbajo-Pescador S.; Porras D.; Garc&#xED;a-Mediavilla M.V.; Mart&#xED;nez-Fl&#xF3;rez S.; Juarez-Fern&#xE1;ndez M.; Cuevas M.J.; Mauriz J.L.; Gonz&#xE1;lez-Gallego J.; Nistal E.; S&#xE1;nchez-Campos S.; Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease. Dis Model Mech  2019,12(5),dmm039206","journal-title":"Dis Model Mech"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","volume":"50","author":"Bence K.K.","year":"2021","unstructured":"Bence K.K.; Birnbaum M.J.; Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab  2021,50,101143","journal-title":"Mol Metab"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10620-021-06824-7","volume":"67","author":"Filippatos T.D.","year":"2022","unstructured":"Filippatos T.D.; Alexakis K.; Mavrikaki V.; Mikhailidis D.P.; Nonalcoholic fatty pancreas disease: Role in Metabolic syndrome, &#x201C;Prediabetes,&#x201D; diabetes and atherosclerosis. Dig Dis Sci  2022,67(1),26-41","journal-title":"Dig Dis Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1053\/j.gastro.2022.01.058","volume":"162","author":"Bauer K.C.","year":"2022","unstructured":"Bauer K.C.; Littlejohn P.T.; Ayala V.; Creus-Cuadros A.; Finlay B.B.; Nonalcoholic fatty liver disease and the gut-liver axis: Exploring an undernutrition perspective. Gastroenterology  2022,162(7),1858-1875","journal-title":"Gastroenterology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2223339","DOI":"10.1080\/19490976.2023.2223339","volume":"15","author":"G&#xF3;mez-P&#xE9;rez A.M.","year":"2023","unstructured":"G&#xF3;mez-P&#xE9;rez A.M.; Ruiz-Lim&#xF3;n P.; Salas-Salvad&#xF3; J.; Vioque J.; Corella D.; Fit&#xF3; M.; Vidal J.; Atzeni A.; Torres-Collado L.; &#xC1;lvarez-Sala A.; Mart&#xED;nez M.&#xC1;.; Goday A.; Benaiges D.; Garc&#xED;a-Gavil&#xE1;n J.; Bernal L&#xF3;pez M.R.; Moreno-Indias I.; Tinahones F.J.; Gut microbiota in nonalcoholic fatty liver disease: A PREDIMED-Plus trial sub analysis. Gut Microbes  2023,15(1),2223339","journal-title":"Gut Microbes"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"134322","DOI":"10.1016\/j.foodchem.2022.134322","volume":"403","author":"Batista K.S.","year":"2023","unstructured":"Batista K.S.; Soares N.L.; Dorand V.A.M.; Alves A.F.; dos Santos Lima M.; de Alencar Pereira R.; Leite de Souza E.; Magnani M.; Persuhn D.C.; de Souza Aquino J.; Acerola fruit by-product alleviates lipid, glucose, and inflammatory changes in the enterohepatic axis of rats fed a high-fat diet. Food Chem  2023,403,134322","journal-title":"Food Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3390\/antiox12091781","volume":"12","author":"Zou Y.","year":"2023","unstructured":"Zou Y.; Yan H.; Li C.; Wen F.; Jize X.; Zhang C.; Liu S.; Zhao Y.; Fu Y.; Li L.; Liu F.; Chen J.; Li R.; Chen X.; Tian M.; A pectic polysaccharide from Codonopsis pilosula alleviates inflammatory response and oxidative stress of aging mice via modulating intestinal microbiota-related gut\u2013liver axis. Antioxidants  2023,12(9),1781","journal-title":"Antioxidants"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"12431","DOI":"10.3390\/ijms222212431","volume":"22","author":"Fling R.R.","year":"2021","unstructured":"Fling R.R.; Zacharewski T.R.; Aryl Hydrocarbon Receptor (AhR) activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) dose-dependently shifts the gut microbiome consistent with the progression of non-alcoholic fatty liver disease. Int J Mol Sci  2021,22(22),12431","journal-title":"Int J Mol Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e13357","DOI":"10.1111\/asj.13357","volume":"91","author":"Suzuki T.","year":"2020","unstructured":"Suzuki T.; Regulation of the intestinal barrier by nutrients: The role of tight junctions. Anim Sci J  2020,91(1),e13357","journal-title":"Anim Sci J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"863779","DOI":"10.3389\/fcimb.2022.863779","volume":"12","author":"Che Q.","year":"2022","unstructured":"Che Q.; Luo T.; Shi J.; He Y.; Xu D.L.; Mechanisms by which traditional chinese medicines influence the intestinal flora and intestinal barrier. Front Cell Infect Microbiol  2022,12,863779","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.gastrohep.2022.12.003","volume":"46","author":"Chen K.","year":"2023","unstructured":"Chen K.; Lin T.; Yao W.; Chen X.; Xiong X.; Huang Z.; Adipocytes-derived exosomal miR-122 promotes non-alcoholic fat liver disease progression via targeting Sirt1. Gastroenterol Hepatol  2023,46(7),531-541","journal-title":"Gastroenterol Hepatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12974-019-1538-9","volume":"16","author":"Zusso M.","year":"2019","unstructured":"Zusso M.; Lunardi V.; Franceschini D.; Pagetta A.; Lo R.; Stifani S.; Frigo A.C.; Giusti P.; Moro S.; Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4\/NF-kB pathway. J Neuroinflammation  2019,16(1),148","journal-title":"J Neuroinflammation"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/bph.14938","volume":"177","author":"Wang Q.","year":"2020","unstructured":"Wang Q.; Ou Y.; Hu G.; Wen C.; Yue S.; Chen C.; Xu L.; Xie J.; Dai H.; Xiao H.; Zhang Y.; Qi R.; Naringenin attenuates non\u2010alcoholic fatty liver disease by down\u2010regulating the NLRP3\/NF\u2010&#x3BA;B pathway in mice. Br J Pharmacol  2020,177(8),1806-1821","journal-title":"Br J Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3350\/cmh.2022.0068","volume":"28","author":"Lee S.M.","year":"2022","unstructured":"Lee S.M.; Koh D.H.; Jun D.W.; Roh Y.J.; Kang H.T.; Oh J.H.; Kim H.S.; Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- &#x3BA;B signaling pathways. Clin Mol Hepatol  2022,28(4),827-840","journal-title":"Clin Mol Hepatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"12969","DOI":"10.21037\/apm-20-1613","volume":"10","author":"Wang T.","year":"2021","unstructured":"Wang T.; Song J.; Hu J.; Feng S.; Zhang H.; Wang H.; Li B.; Efficacy and safety of Huazhi Rougan granule in the treatment of non-alcoholic fatty liver: A systematic review and meta-analysis. Ann Palliat Med  2021,10(12),12969-12984","journal-title":"Ann Palliat Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"875700","DOI":"10.3389\/fphar.2022.875700","volume":"13","author":"Liu Y.","year":"2022","unstructured":"Liu Y.; Tan Y.; Huang J.; Wu C.; Fan X.; Stalin A.; Lu S.; Wang H.; Zhang J.; Zhang F.; Wu Z.; Li B.; Huang Z.; Chen M.; Cheng G.; Mou Y.; Wu J.; Revealing the mechanism of huazhi rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology. Front Pharmacol  2022,13,875700","journal-title":"Front Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"Ipsen D.H.","year":"2018","unstructured":"Ipsen D.H.; Lykkesfeldt J.; Tveden-Nyborg P.; Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci  2018,75(18),3313-3327","journal-title":"Cell Mol Life Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","volume":"25","author":"Long J.K.","year":"2019","unstructured":"Long J.K.; Dai W.; Zheng Y.W.; Zhao S.P.; miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med  2019,25(1),26","journal-title":"Mol Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.alcohol.2004.06.008","volume":"34","author":"Purohit V.","year":"2004","unstructured":"Purohit V.; Russo D.; Coates P.M.; Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: Introduction and summary of the symposium. Alcohol  2004,34(1),3-8","journal-title":"Alcohol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3390\/nu11102536","volume":"11","author":"Mun J.","year":"2019","unstructured":"Mun J.; Kim S.; Yoon H.G.; You Y.; Kim O.K.; Choi K.C.; Lee Y.H.; Lee J.; Park J.; Jun W.; Water extract of Curcuma longa L. ameliorates non-alcoholic fatty liver disease. Nutrients  2019,11(10),2536","journal-title":"Nutrients"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.foodchem.2013.11.058","volume":"151","author":"Kim Y.","year":"2014","unstructured":"Kim Y.; You Y.; Yoon H.G.; Lee Y.H.; Kim K.; Lee J.; Kim M.S.; Kim J.C.; Jun W.; Hepatoprotective effects of fermented Curcuma longa L. on carbon tetrachloride-induced oxidative stress in rats. Food Chem  2014,151,148-153","journal-title":"Food Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1124\/pr.108.00001","volume":"60","author":"Anderson N.","year":"2008","unstructured":"Anderson N.; Borlak J.; Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev  2008,60(3),311-357","journal-title":"Pharmacol Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"Pawlak M.","year":"2015","unstructured":"Pawlak M.; Lefebvre P.; Staels B.; Molecular mechanism of PPAR&#x3B1; action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol  2015,62(3),720-733","journal-title":"J Hepatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ajpath.2012.10.014","volume":"182","author":"Guo S.","year":"2013","unstructured":"Guo S.; Al-Sadi R.; Said H.M.; Ma T.Y.; Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol  2013,182(2),375-387","journal-title":"Am J Pathol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3164\/jcbn.13-49","volume":"54","author":"Fukunishi S.","year":"2014","unstructured":"Fukunishi S.; Sujishi T.; Takeshita A.; Ohama H.; Tsuchimoto Y.; Asai A.; Tsuda Y.; Higuchi K.; Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J Clin Biochem Nutr  2014,54(1),39-44","journal-title":"J Clin Biochem Nutr"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/diagnostics9040205","volume":"9","author":"Maciejewska D.","year":"2019","unstructured":"Maciejewska D.; \u0141ukomska A.; Dec K.; Skonieczna-&#x17B;ydecka K.; Gutowska I.; Sk&#xF3;rka-Majewicz M.; Styburski D.; Misiakiewicz-Has K.; Pilutin A.; Palma J.; Sieletycka K.; Marlicz W.; Stachowska E.; Diet-Induced Rat Model of Gradual development of Non-Alcoholic Fatty Liver Disease (NAFLD) with Lipopolysaccharides (LPS) Secretion. Diagnostics (Basel)  2019,9(4),205","journal-title":"Diagnostics (Basel)"},{"key":"ref=29","first-page":"136","volume":"61","author":"Xin D.","year":"2014","unstructured":"Xin D.; Zong-Shun L.; Bang-Mao W.; Lu Z.; Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease. Hepatogastroenterology  2014,61(129),136-140","journal-title":"Hepatogastroenterology"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/13880209.2022.2126503","volume":"60","author":"Shen S.","year":"2022","unstructured":"Shen S.; Wang K.; Zhi Y.; Dong Y.; Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4\/nuclear factor kappa B pathways. Pharm Biol  2022,60(1),1949-1959","journal-title":"Pharm Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/2211536607666180531093302","volume":"7","author":"Jampoka K.","year":"2018","unstructured":"Jampoka K.; Muangpaisarn P.; Khongnomnan K.; Treeprasertsuk S.; Tangkijvanich P.; Payungporn S.; Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD). MicroRNA  2018,7(3),215-222","journal-title":"MicroRNA"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.lfs.2018.07.029","volume":"208","author":"Ye D.","year":"2018","unstructured":"Ye D.; Zhang T.; Lou G.; Xu W.; Dong F.; Chen G.; Liu Y.; Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci  2018,208,201-207","journal-title":"Life Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12876-016-0557-6","volume":"16","author":"Akuta N.","year":"2016","unstructured":"Akuta N.; Kawamura Y.; Suzuki F.; Saitoh S.; Arase Y.; Fujiyama S.; Sezaki H.; Hosaka T.; Kobayashi M.; Suzuki Y.; Kobayashi M.; Ikeda K.; Kumada H.; Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol  2016,16(1),141","journal-title":"BMC Gastroenterol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"902","DOI":"10.5152\/tjg.2020.19568","volume":"31","author":"Wang L.","year":"2021","unstructured":"Wang L.; Jia Z.; Wang B.; Zhang B.; Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4\/MyD88\/NF-&#x3BA;B pathway. Turk J Gastroenterol  2021,31(12),902-909","journal-title":"Turk J Gastroenterol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"154410","DOI":"10.1016\/j.prp.2023.154410","volume":"244","author":"Tang Y.L.","year":"2023","unstructured":"Tang Y.L.; Zhu L.; Tao Y.; Lu W.; Cheng H.; Role of targeting TLR4 signaling axis in liver-related diseases. Pathol Res Pract  2023,244,154410","journal-title":"Pathol Res Pract"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113862073290372240603090844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/236402\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113862073290372240603090844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T04:09:27Z","timestamp":1763611767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/236402\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113862073290372240603090844","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-12-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}